Search

Displaying results 2561 - 2570 of 10000 in total
  1. Drug

    Estradiol dienanthate

    go.drugbank.com/drugs/DB13955
    ApprovedVet approvedWithdrawn

    in various tissues including in the breasts, uterus, ovaries, skin, prostate, bone, fat, and brain. … Estradiol dienanthate is not currently available in any commercially available products in Canada or the US.

  2. Drug

    Esculin

    go.drugbank.com/drugs/DB13155
    Approved

    Esculin is found in barley. … ) and in daphnin (the dark green resin of Daphne mezereum).

  3. Drug

    Daraxonrasib

    go.drugbank.com/drugs/DB22308
    ApprovedInvestigational

    [L64039] It is a RAS(ON) tri-complex inhibitor that binds cyclophilin A and targets the active, GTP-bound ("ON") state of RAS, suppressing signaling of both wild-type and mutant RAS across the most common … Daraxonrasib is an orally administered, multi-selective inhibitor of the RAS GTPase family used to treat metastatic pancreatic adenocarcinoma.

  4. Drug

    Pinaverium

    go.drugbank.com/drugs/DB09090
    ApprovedInvestigational

    Pinaverium bromide is the common ingredient in formulations, mostly as oral tablets. … It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function.

  5. Drug

    Cipaglucosidase alfa

    go.drugbank.com/drugs/DB16708
    ApprovedInvestigational

    in Pompe disease. … ,[L45275] and the EMA fully approved the drug on March 27, 2023.

  6. Drug

    Allogeneic processed thymus tissue

    go.drugbank.com/drugs/DB16736
    Approved

    [A239814] On October 8, 2021, FDA approved allogeneic processed thymus tissue-agdc, under the market name RETHYMIC, as a one-time regenerative tissue-based therapy for immune reconstitution in pediatric … Allogeneic processed thymus tissue is used for immune reconstitution in immune disorders where the patients are severely immunocompromised due to the absence of a functional thymus, such as congenital

  7. Drug

    Fexapotide

    go.drugbank.com/drugs/DB05493
    Investigational

    NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed.

    Categories: Drugs Used in Benign Prostatic Hypertrophy
  8. Drug

    Tea tree oil

    go.drugbank.com/drugs/DB11218
    ApprovedNutraceutical

    Tea tree oil is an essential oil derived mainly from the Australian native plant _Melaleuca alternifolia_ via steam distillation of the of the leaves and terminal branches [A32439]. … It has been a popular ingredient in a variety of household and cosmetic products due to its antiseptic, anti-inflammatory, broad-spectrum antimicrobial and antioxidant properties [A32438].

    Synonyms: Snow-in-summer leaf oil
  9. Drug

    Tinzaparin

    go.drugbank.com/drugs/DB06822
    ApprovedInvestigational

    It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. … It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons.

    Products: innohep 8.000 IE/0,4 ml Injektionslösung in einer Fertigspritze, innohep 10.000 IE/0,5 ml Injektionslösung in einer Fertigspritze
  10. Drug

    Bosentan

    go.drugbank.com/drugs/DB00559
    ApprovedInvestigational

    Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise pr...

    Synonyms: 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide, p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamideProducts: N/A